Quanren Wang

929 total citations
25 papers, 440 citations indexed

About

Quanren Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Quanren Wang has authored 25 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Quanren Wang's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Quanren Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Quanren Wang collaborates with scholars based in China, United States and Hong Kong. Quanren Wang's co-authors include Jieqiong Liu, Qian Li, Ying Li, Qiang Liu, Ying Wang, Zefei Jiang, Shicheng Su, Fengxi Su, Liang Jin and Erwei Song and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Business Research and BMC Medicine.

In The Last Decade

Quanren Wang

25 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Quanren Wang China 11 314 169 103 77 76 25 440
Erkki‐Ville Wirta Finland 10 303 1.0× 87 0.5× 91 0.9× 51 0.7× 94 1.2× 27 402
Guoqiang Wang China 9 455 1.4× 227 1.3× 62 0.6× 89 1.2× 101 1.3× 24 561
Depei Huang China 10 340 1.1× 197 1.2× 51 0.5× 90 1.2× 69 0.9× 24 482
Wang‐Zhong Li China 13 275 0.9× 116 0.7× 129 1.3× 61 0.8× 58 0.8× 41 523
Mariachiara Santorsola Italy 13 218 0.7× 92 0.5× 85 0.8× 121 1.6× 39 0.5× 45 428
Geoff Chong Australia 9 274 0.9× 117 0.7× 105 1.0× 64 0.8× 62 0.8× 25 414
Longgang Cui China 7 297 0.9× 159 0.9× 42 0.4× 61 0.8× 65 0.9× 17 383
Boyang Chang China 12 224 0.7× 94 0.6× 90 0.9× 142 1.8× 84 1.1× 26 458
Elisa Tassinari Italy 8 217 0.7× 205 1.2× 84 0.8× 145 1.9× 52 0.7× 34 457

Countries citing papers authored by Quanren Wang

Since Specialization
Citations

This map shows the geographic impact of Quanren Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quanren Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quanren Wang more than expected).

Fields of papers citing papers by Quanren Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quanren Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quanren Wang. The network helps show where Quanren Wang may publish in the future.

Co-authorship network of co-authors of Quanren Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Quanren Wang. A scholar is included among the top collaborators of Quanren Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quanren Wang. Quanren Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gao, Jia, Fang Wang, Xiaoling Wang, et al.. (2024). Safety and efficacy of a novel dexmedetomidine nasal spray for pre-anesthetic sedation in children: a randomized, double-blind, placebo-controlled trial. BMC Anesthesiology. 24(1). 315–315. 3 indexed citations
2.
Li, Huiying, et al.. (2024). Central government Ownership, geographic Distance, and firm Innovation: Evidence from Chinese State-owned enterprises. Journal of Business Research. 186. 115033–115033. 1 indexed citations
3.
4.
5.
Xia, Lingfang, Jin Peng, Ge Lou, et al.. (2022). Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. Journal for ImmunoTherapy of Cancer. 10(1). e003831–e003831. 22 indexed citations
6.
Ren, Shengxiang, Jianxing He, Yong Fang, et al.. (2022). Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. JTO Clinical and Research Reports. 3(5). 100312–100312. 19 indexed citations
7.
Li, Huiping, Rutie Yin, Youzhong Zhang, et al.. (2022). A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.. Journal of Clinical Oncology. 40(16_suppl). 5539–5539. 1 indexed citations
8.
Qu, Yuanyuan, Zhongquan Sun, Weiqing Han, et al.. (2022). Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study. Journal for ImmunoTherapy of Cancer. 10(5). e004427–e004427. 18 indexed citations
9.
Liu, Jieqiong, Ying Li, Qian Li, et al.. (2021). Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Research and Treatment. 186(3). 687–697. 27 indexed citations
10.
Qu, Yuanyuan, Qing Zou, Hongqian Guo, et al.. (2021). Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.. Journal of Clinical Oncology. 39(15_suppl). 4550–4550. 2 indexed citations
11.
Zhang, Yun, Jianming Xu, Jie Shen, et al.. (2021). Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(15_suppl). 4076–4076. 8 indexed citations
12.
Li, Huiping, Rongrui Liu, Bin Shao, et al.. (2020). Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research. 32(3). 370–382. 22 indexed citations
13.
Wang, Nan, Kun Li, Xiaoran Liu, et al.. (2020). Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. Chinese Journal of Cancer Research. 32(2). 149–162. 13 indexed citations
14.
Zhu, Yunting, Yunpeng Liu, Xiujuan Qu, et al.. (2020). <p>Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors</p>. Drug Design Development and Therapy. Volume 14. 1963–1970. 9 indexed citations
15.
Chen, Xiaofeng, Xiaofeng Wu, Hao Wu, et al.. (2020). SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer.. Journal of Clinical Oncology. 38(4_suppl). 535–535. 3 indexed citations
16.
Zhou, Caicun, Guanghui Gao, Jun Zhao, et al.. (2019). Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.. Journal of Clinical Oncology. 37(15_suppl). 9112–9112. 22 indexed citations
17.
Xu, Jianming, Rongrui Liu, Yi Ba, et al.. (2019). Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 37(15_suppl). 4060–4060. 4 indexed citations
18.
Zhou, Caicun, Guanghui Gao, Fengying Wu, et al.. (2018). A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 36(15_suppl). e21017–e21017. 10 indexed citations
19.
20.
Liu, Xiaoyun, Yifan Zhang, Qian Chen, et al.. (2017). Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole. The Journal of Clinical Pharmacology. 58(3). 347–356. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erkki‐Ville Wirta Breakdown of academic impact, for papers by Guoqiang Wang Breakdown of academic impact, for papers by Depei Huang Breakdown of academic impact, for papers by Wang‐Zhong Li Breakdown of academic impact, for papers by Mariachiara Santorsola Breakdown of academic impact, for papers by Geoff Chong Breakdown of academic impact, for papers by Longgang Cui Breakdown of academic impact, for papers by Boyang Chang Breakdown of academic impact, for papers by Elisa Tassinari
Rankless by CCL
2026